CARDS: The Collaborative Atorvastatin Diabetes Study - PowerPoint PPT Presentation

1 / 8
About This Presentation
Title:

CARDS: The Collaborative Atorvastatin Diabetes Study

Description:

Colhoun HM, Betteridge PN, Hitman GA et al. Primary prevention of cardiovascular ... to all cause mortality, major coronary events, coronary revascularization, ... – PowerPoint PPT presentation

Number of Views:50
Avg rating:3.0/5.0
Slides: 9
Provided by: inci2
Category:

less

Transcript and Presenter's Notes

Title: CARDS: The Collaborative Atorvastatin Diabetes Study


1
CARDS The Collaborative Atorvastatin Diabetes
Study
  • Purpose
  • To assess the effectiveness of 10 mg
    atorvastatin daily in the primary prevention of
    cardiovascular disease in patients with type 2
    diabetes, but without high concentrations of
    LDL-cholesterol
  • Reference
  • Colhoun HM, Betteridge PN, Hitman GA et al.
    Primary prevention of cardiovascular disease with
    atorvastatin in the Collaborative Atorvastatin
    Diabetes Study (CARDS) multicentre randomised
    placebo-controlled trial. Lancet
    2004264685696.

2
CARDS The Collaborative Atorvastatin Diabetes
Study - TRIAL DESIGN -
  • Design
  • Multicenter, multinational, randomized,
    double-blind, parallel group
  • Patients
  • 2838 patients aged 40-75 yrs with type 2
    diabetes mellitus and at least one of
    hypertension, retinopathy, albuminuria, smoking.
    Patients with history of MI, angina, coronary
    vascular surgery, cerebrovascular accident or
    severe peripheral vascular disease ineligible
  • Follow up and primary endpoint
  • Primary endpoint acute coronary event, coronary
    revascularization, or stroke. Median 3.9 years
    follow-up
  • Treatment
  • Atorvastatin 10 mg per day or placebo

3
CARDS The Collaborative Atorvastatin Diabetes
Study - TRIAL DESIGN continued-
Baseline characteristics
4
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS -
  • Compared with placebo, patients receiving 10 mg
    atorvastatin daily showed a 37 reduction in
    major cardiovascular events from 9.0 to 5.8 (p
    0.001)
  • There was a favourable trend in the atorvastatin
    group with regard to all cause mortality, acute
    coronary events, coronary revascularization, and
    stroke
  • Adverse event rate similar in atorvastatin and
    placebo groups.
  • No cases of rhabdomyolysis.

5
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -

6
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -
Breakdown of primary endpoint by treatment
7
CARDS The Collaborative Atorvastatin Diabetes
Study - RESULTS continued -
8
CARDS The Collaborative Atorvastatin Diabetes
Study - SUMMARY -
  • Atorvastatin (10 mg, once daily) is safe and
    effective in reducing the risk of cardiovascular
    events, including stroke, in patients with type 2
    diabetes
  • There was a favourable trend in the atorvastatin
    group with regard to all cause mortality, major
    coronary events, coronary revascularization, and
    stroke
Write a Comment
User Comments (0)
About PowerShow.com